Abstract: . . .  lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood. 2005 [Epub ahead of print]. 41. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol. 2003;121:101-103. For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. For personal use. Mass reproduce only with permission from . . .
. . .  (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma [abstract]. Haematologica. 2005;90(suppl 2):160. Abstract 0402. 40. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood. 2005 [Epub ahead of print]. 41. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome . . .
. . .  overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067. 39. Dimopoulos M, Weber D, Chen C, et al. Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma [abstract]. Haematologica. 2005;90(suppl 2):160. Abstract 0402. 40. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone . . .
. . .  2002;13:1029-1035. 33. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thali- domide administration in patients with neoplastic diseases. Am J Med. 2004; 117:508-515. 34. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355:1295-1302. 35. Hansen KE, Kramm HL, Boh D, et al. Risk factors for thrombosis and the beneficial effect of aspirin in . . .
. . .  aspirin in patients with antiphospholipid antibodies (aPL) [abstract]. Blood. 2004;104:83a. Abstract 279. 36. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235-246. 37. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth . . .
. . .  patients with antiphospholipid antibodies (aPL) [abstract]. Blood. 2004;104:83a. Abstract 279. 36. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235-246. 37. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs . . .
--3000,6,250,3453,23166